Systematic Screening of COVID-19 Disease Based on Chest CT and RT-PCR for Cancer Patients Undergoing Radiation Therapy in a Coronavirus French Hotspot.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
15 07 2021
Historique:
received: 09 07 2020
revised: 10 02 2021
accepted: 10 02 2021
pubmed: 21 2 2021
medline: 1 7 2021
entrez: 20 2 2021
Statut: ppublish

Résumé

Patients with cancer are presumed to be more vulnerable to COVID-19. We evaluated a screening strategy combining chest computed tomography (CT) and reverse-transcription polymerase chain reaction (RT-PCR) for patients treated with radiation therapy at our cancer center located in a COVID-19 French hotspot during the first wave of the pandemic. Chest CT images were proposed during radiation therapy CT simulation. Images were reviewed by an expert radiologist according to the COVID-19 Reporting and Data System classification. Nasal swabs with RT-PCR assay were initially proposed in cases of suspicious imaging or clinical context and were eventually integrated into the systematic screening. A dedicated radiation therapy workflow was proposed for COVID-19 patients to limit the risk of contamination. From March 18, 2020 to May 1, 2020, 480 patients were screened by chest CT, and 313 patients had both chest CT and RT-PCR (65%). The cumulative incidence of COVID-19 was 5.4% (95% confidence interval [CI], 3.6-7.8; 26 of 480 patients). Diagnosis of COVID-19 was made before radiation therapy for 22 patients (84.6%) and during RT for 4 patients (15.3%). Chest CT directly aided the diagnosis of 7 cases in which the initial RT-PCR was negative or not feasible, out of a total of 480 patients (1.5%) and 517 chest CT acquisitions. Four patients with COVID-19 at the time of the chest CT screening had a false negative CT. Sensitivity and specificity of chest CT screening in patients with both RT-PCR and chest CT testing were estimated at 0.82 (95% CI, 0.60-0.95) and 0.98 (95% CI, 0.96-0.99), respectively. Adaptation of the radiation therapy treatment was made for all patients, with 7 postponed treatments (median: 5 days; interquartile range, 1.5-14.8). The benefit of systematic use of chest CT screening during CT simulation for patients undergoing radiation therapy during the COVID-19 pandemic seemed limited.

Identifiants

pubmed: 33609591
pii: S0360-3016(21)00197-8
doi: 10.1016/j.ijrobp.2021.02.022
pmc: PMC7887448
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

947-956

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Références

Eur J Cancer. 2020 Aug;135:251-259
pubmed: 32540204
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Radiol Cardiothorac Imaging. 2020 Mar 25;2(2):e200152
pubmed: 33778571
Innovation (Camb). 2020 Nov 25;1(3):100061
pubmed: 33169119
Nat Cancer. 2020 Oct;1(10):965-975
pubmed: 35121871
Radiology. 2020 Aug;296(2):E97-E104
pubmed: 32339082
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
Radiology. 2020 Sep;296(3):E145-E155
pubmed: 32301646
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541
Phys Med Biol. 2012 Nov 21;57(22):7725-39
pubmed: 23123826
Radiology. 2021 Feb;298(2):E81-E87
pubmed: 32870139
Front Oncol. 2020 Nov 18;10:556334
pubmed: 33312944
Cancer Discov. 2021 Feb;11(2):233-236
pubmed: 33355178
Crit Rev Oncol Hematol. 2020 Jun;150:102972
pubmed: 32344317
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541

Auteurs

Roger Sun (R)

Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Gustave Roussy, Villejuif, France.

Samir Achkar (S)

Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Samy Ammari (S)

Department of Radiology, Gustave Roussy, Paris-Saclay University, Villejuif, France; BioMaps (UMR1281), Université Paris-Saclay, CNRS, INSERM, CEA, Orsay and Gustave Roussy, Villejuif, France.

Sophie Bockel (S)

Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Emmanuelle Gallois (E)

Department of Biopathology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Arnaud Bayle (A)

Department of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Enzo Battistella (E)

Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Gustave Roussy, Villejuif, France.

Flore Salviat (F)

Department of Biostatistics, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Mansouria Merad (M)

Department of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Adrien Laville (A)

Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Kanta Ka (K)

Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Franck Griscelli (F)

Department of Biopathology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Laurence Albiges (L)

Department of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Fabrice Barlesi (F)

Department of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Alberto Bossi (A)

Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Sofia Rivera (S)

Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Cyrus Chargari (C)

Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Gustave Roussy, Villejuif, France.

Eric Deutsch (E)

Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Gustave Roussy, Villejuif, France. Electronic address: eric.deutsch@gustaveroussy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH